HA liposomes showed a favorable drug-release profile and higher toxicity in vitro and in vivo than DOX or Caelyx (commercial DOX-loaded PEGylated liposomes) against Pgp-overexpressing osteosarcoma. Here, PGP is linked to osteosarcoma.